denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: Chasing Zebras: Navigating Rare Myeloid Neoplasms
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Disclosures: Pemmaraju: Pacylex: Consultancy; Affymetrix/Thermo Fisher Scientific: Research Funding; Triptych Health Partners: Consultancy; CareDx: Honoraria; CTI BioPharma: Consultancy; Incyte: Honoraria; LFB Biotechnologies: Honoraria; Mustang Bio: Honoraria, Other: Travel Expenses, Research Funding; Springer Science + Business Media: Honoraria; Stemline Therapeutics: Honoraria, Other: Travel Expenses, Research Funding; Roche Molecular Diagnostics: Honoraria; Bristol-Myers Squibb: Consultancy; DAVA Oncology: Honoraria, Other: Travel Expenses; Aptitude Health: Honoraria; Novartis: Honoraria, Research Funding; Protagonist Therapeutics: Consultancy; Celgene: Honoraria, Other: Travel Expenses; Neopharm: Honoraria; ClearView Healthcare Partners: Consultancy; Blueprint Medicines: Consultancy, Honoraria; Immunogen: Consultancy; Daiichi Sankyo: Research Funding; Cellectis: Research Funding; Plexxikon: Research Funding; Samus Therapeutics: Research Funding; Blueprint Medicines OncLive PeerView Institute for Medical Education: Consultancy, Other: advisory board; Astellas: Consultancy; AbbVie: Honoraria, Other: Travel Expenses, Research Funding; ASH Committee on Communications ASCO Cancer.NET Editorial Board: Other: Leadership; Karger Publishers: Other: Licenses; National Institute of Health/National Cancer Institute (NIH/NCI): Research Funding; HemOnc Times/Oncology Times: Other: uncompensated.